Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (...
Background: The therapeutic advancements based on immune-oncology (IO) combinations have revolutionized renal cell carcinoma (RCC) management. However, patients who have progressive disease as best result, "primary refractory” (Pref), face dismal …